Markets:

Overview

News

Currencies

International

Treasuries

iShares Biotechnology ETF (NQ:IBB)

174.01 +3.37 (+1.97%)

Streaming Delayed Price Updated: 11:52 AM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗

September 26, 2025

Via Stocktwits

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Small Cap Revival: Could Rate Cuts Spark a Rebound in Smaller Companies?

September 17, 2025

As whispers of impending interest rate cuts grow louder from central banks worldwide, a new wave of optimism is beginning to ripple through the often-overlooked small-cap sector. These nimble,...

Via MarketMinute

Topics Economy

Biotech Sector May Flip to Market Leader by Year-End ↗

September 15, 2025

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

Via MarketBeat

Topics ETFs Economy Stocks

CDC Turmoil Escalates: Kennedy To Testify In Senate After Director Fired, Senior Officials Quit ↗

August 28, 2025

Via Stocktwits

CDC Chief Susan Monarez Pushed Out After Weeks On Job As RFK Jr. Overhauls Agency — She’s Fighting Back ↗

August 27, 2025

Via Stocktwits

Major Sector ETFs Wildcard: Biotechnology ↗

March 03, 2025

On the weekly chart, IBB is breaking under the 200-week moving average.

Via Talk Markets

Topics ETFs

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Via Benzinga

Topics ETFs Government

FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market ↗

July 18, 2025

The FDA had already been investigating two earlier deaths linked to Elevidys.

Via Stocktwits

Topics Death

Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn ↗

July 16, 2025

President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month.

Via Investor's Business Daily

Topics ETFs Government World Trade

Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs ↗

July 08, 2025

President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."

Via Investor's Business Daily

Topics ETFs Economy Government

US Supreme Court Reportedly Upholds Part Of Obamacare That Guarantees Health Insurers Cover Preventive Care ↗

June 27, 2025

The Obamacare law requires health insurers to provide preventive care, including cancer screenings and HIV prevention medication, at no cost to patients.

Via Stocktwits

Topics Government Lawsuit Religion

Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗

May 19, 2025

Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.

Via Benzinga

Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns ↗

May 06, 2025

President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new...

Via Benzinga

Topics Government World Trade

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

The Major Sector ETFs Got Their Story ↗

April 27, 2025

XRT has more work to do. At best, the consumer sector is trying to bottom. At worst, this is a rally into resistance.

Via Talk Markets

Topics ETFs

Major Sector ETFs Break For Easter ↗

April 16, 2025

SMH holds steadfast above the 200-WMA even in the face of the tariffs and chip ban to China.

Via Talk Markets

Topics Cryptocurrencies ETFs World Trade

RFK Jr.'s Massive Federal Health Workforce Cut Could Take 'Decades To Rebuild,' Warn Experts: 'We Cannot Accurately Assess Whether We Are Truly Making America Healthier' ↗

April 14, 2025

Experts raise alarms about Health Secretary Robert F. Kennedy Jr's decision to layoff tens of thousands of federal workers, disrupting critical health data collection and research efforts.

Via Benzinga

Topics Workforce

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger ↗

March 25, 2025

Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.

Via Stocktwits

Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw? ↗

March 25, 2025

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.

Via Stocktwits

Can Buying In The Broader Market Pick Up Steam? ↗

March 16, 2025

Both SPY and QQQ must get back over and close above their 50-WMA to convince bulls the move Friday, while a reversal in the works, is not just a dead cat bounce.

Via Talk Markets

Topics ETFs

BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic ↗

March 10, 2025

For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.

Via Stocktwits

Healthcare Sector Trying To Bounce Back ↗

March 09, 2025

I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector.

Via Talk Markets

Topics ETFs Stocks / Equities

March Came In Like A Lion - Key Sectors Are Looking For A Lamb ↗

March 09, 2025

Looking at the monthly chart, XRT now sits back in economic contraction, or below the 23-month moving average.

Via Talk Markets

Topics ETFs

Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential ↗

March 05, 2025

The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.

Via Stocktwits

Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars? ↗

March 04, 2025

Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as...

Via Talk Markets

Topics ETFs Stocks / Equities

Biotech Rally Coming In Weeks Ahead? ↗

March 04, 2025

Large cap biopharma and MedTech stocks are leading the healthcare sector higher.

Via Talk Markets

Topics ETFs Stocks / Equities

Semiconductors Fail A Key Support Level - And More ↗

March 02, 2025

It has been 2 years and 2 months since the ETF for Semiconductors SMH has traded below the 50-week moving average.

Via Talk Markets

Topics ETFs

4 Sectors That Thrive When Inflation Runs Hot

February 28, 2025

Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value

Via MarketBeat

Topics Economy World Trade

PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? ↗

February 28, 2025

The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.